JP2023551122A5 - - Google Patents
Info
- Publication number
- JP2023551122A5 JP2023551122A5 JP2023528102A JP2023528102A JP2023551122A5 JP 2023551122 A5 JP2023551122 A5 JP 2023551122A5 JP 2023528102 A JP2023528102 A JP 2023528102A JP 2023528102 A JP2023528102 A JP 2023528102A JP 2023551122 A5 JP2023551122 A5 JP 2023551122A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- nk2r
- formula
- agonist according
- agonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20206509.0 | 2020-11-09 | ||
| EP20206509 | 2020-11-09 | ||
| PCT/EP2021/081057 WO2022096736A1 (en) | 2020-11-09 | 2021-11-09 | Compounds and their use in treatment of tachykinin receptor mediated disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023551122A JP2023551122A (ja) | 2023-12-07 |
| JP2023551122A5 true JP2023551122A5 (enExample) | 2024-10-30 |
Family
ID=73198203
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023528102A Ceased JP2023551122A (ja) | 2020-11-09 | 2021-11-09 | 化合物およびタキキニン受容体介在性障害の治療におけるその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230406883A1 (enExample) |
| EP (1) | EP4240749A1 (enExample) |
| JP (1) | JP2023551122A (enExample) |
| KR (1) | KR20230106616A (enExample) |
| CN (1) | CN116745310A (enExample) |
| AU (1) | AU2021374843A1 (enExample) |
| CA (1) | CA3197916A1 (enExample) |
| CL (1) | CL2023001325A1 (enExample) |
| CO (1) | CO2023007404A2 (enExample) |
| IL (1) | IL302745A (enExample) |
| MX (1) | MX2023005408A (enExample) |
| PE (1) | PE20231952A1 (enExample) |
| WO (1) | WO2022096736A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240118914A (ko) | 2021-01-20 | 2024-08-05 | 바이킹 테라퓨틱스 인코포레이티드 | 대사 및 간 질환 치료를 위한 조성물 및 방법 |
| CA3231953A1 (en) | 2021-09-15 | 2023-03-23 | Brian Lian | Compositions and methods for the treatment of metabolic and liver disorders |
| WO2023118263A1 (en) * | 2021-12-21 | 2023-06-29 | Embark Biotech Aps | Agonists for treatment of eating disorder |
| CN117384258B (zh) * | 2023-10-12 | 2024-07-26 | 湖南中晟全肽生物科技股份有限公司 | 一种神经激肽受体2（nk2r）激动剂及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2660247A3 (en) * | 2009-05-08 | 2014-09-03 | Chongxi Yu | High penetration prodrug compositions of peptides and peptide-related compounds |
| CA2918245C (en) * | 2013-08-01 | 2022-08-30 | Dignify Therapeutics, Inc. | Compositions and methods for inducing urinary voiding and defecation |
| WO2015071355A1 (en) * | 2013-11-15 | 2015-05-21 | Novo Nordisk A/S | Selective pyy compounds and uses thereof |
| MX392572B (es) * | 2015-06-12 | 2025-03-24 | Novo Nordisk As | Compuestos del péptido yy (pyy) selectivos y sus usos. |
| US11352391B2 (en) * | 2017-09-21 | 2022-06-07 | Dignify Therapeutics, Llc | Compositions for inducing urinary voiding and defecation |
| PE20210473A1 (es) * | 2018-05-04 | 2021-03-08 | Novo Nordisk As | Derivados de gip y usos de estos |
| KR20220084035A (ko) * | 2019-10-17 | 2022-06-21 | 유니버시티 오브 코펜하겐 | Tacr2의 효능제 |
-
2021
- 2021-11-09 IL IL302745A patent/IL302745A/en unknown
- 2021-11-09 CN CN202180089751.3A patent/CN116745310A/zh active Pending
- 2021-11-09 WO PCT/EP2021/081057 patent/WO2022096736A1/en not_active Ceased
- 2021-11-09 PE PE2023001563A patent/PE20231952A1/es unknown
- 2021-11-09 CA CA3197916A patent/CA3197916A1/en active Pending
- 2021-11-09 JP JP2023528102A patent/JP2023551122A/ja not_active Ceased
- 2021-11-09 AU AU2021374843A patent/AU2021374843A1/en active Pending
- 2021-11-09 MX MX2023005408A patent/MX2023005408A/es unknown
- 2021-11-09 EP EP21802379.4A patent/EP4240749A1/en active Pending
- 2021-11-09 KR KR1020237016448A patent/KR20230106616A/ko active Pending
- 2021-11-09 US US18/252,056 patent/US20230406883A1/en active Pending
-
2023
- 2023-05-08 CL CL2023001325A patent/CL2023001325A1/es unknown
- 2023-06-05 CO CONC2023/0007404A patent/CO2023007404A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2485135C2 (ru) | Соединения оксинтомодулина (варианты), фармацевтическая композиция на их основе, способы лечения и профилактики ожирения и сопутствующих заболеваний (варианты) и лекарственное средство (варианты) | |
| CN105451755B (zh) | 铁调素类似物和其用途 | |
| AU2007240313B2 (en) | GLP-1 compounds | |
| JP2010536333A5 (enExample) | ||
| JP2011502159A5 (enExample) | ||
| JP2004521123A5 (enExample) | ||
| IL277483B1 (en) | New anti-GLP-1 analogs | |
| US20080020978A1 (en) | CGRP peptide antagonists and conjugates | |
| JP2005530732A5 (enExample) | ||
| JP2002206000A5 (enExample) | ||
| HRP20240906T1 (hr) | Agonisti crf2 receptora i njihova primjena u terapiji | |
| JP2006514104A5 (enExample) | ||
| TW202140513A (zh) | 人類運鐵蛋白受體結合肽 | |
| JP2005516996A5 (enExample) | ||
| CN120981479A (zh) | Gip/glp1/gcg三受体激动剂及其用途 | |
| AU2022222674A1 (en) | Glucagon-like peptide-1 receptor antagonists | |
| JP2025525217A (ja) | グルカゴン様ペプチド－１受容体アンタゴニスト | |
| JP2009519212A5 (enExample) | ||
| JP2008517998A5 (enExample) | ||
| JP2021506815A5 (enExample) | ||
| WO2019165346A1 (en) | Compounds and methods for treating tight junction permeability | |
| WO2012142706A1 (en) | Growth hormone releasing factor (grf) analogs and uses thereof | |
| JP2024512895A5 (enExample) | ||
| JP2967956B2 (ja) | ペプチドまたはその塩 | |
| JP2009502976A (ja) | 親水性ペプチド鎮痛薬の経口送達のためのペプチドコンジュゲート |